FMR Sells Shares in Beam Therapeutics

Despite a recent sale, FMR LLC and affiliates remain major stakeholders in Beam through multiple investment arms.

October 30, 2025

Modest Sell-Off, Broader Structure

On October 27, 2025, FMR LLC made a small move in its Beam Therapeutics Inc. position, selling 459 shares of common stock at $26.68 per share. The transaction, officially reported on October 29, doesn’t shift the overall picture much—but it does offer a clear window into how FMR and its affiliates manage exposure across their investment platforms.

The sale reduced one specific portion of FMR’s indirect holdings, which are spread across several entities. Post-transaction, FMR’s total reported position in Beam stands at 1,980,688 shares. Of that, 1,139,443 shares are held through F-Prime Capital Partners Healthcare Fund V LP. Another 841,231 shares fall under the category of assets managed or held by other FMR-affiliated entities.

What’s important here is how the structure works. These shares aren’t held by FMR LLC directly. Instead, they’re spread across multiple affiliates, each with its own reporting and management layers.

Layered Management and Voting Control

FMR Capital, Inc., which is fully owned by FMR LLC, holds a portion. The healthcare fund is managed by F-Prime Capital Partners Healthcare Advisors Fund V LP, which in turn is managed by Impresa Management LLC.

The Johnson family—particularly Abigail P. Johnson, FMR’s Chairman and CEO—plays a central role in how the broader organization exercises control. The family holds significant voting power through Series B shares and a coordinated voting agreement. This setup enables the group to act with unified direction when it comes to major decisions across the investment business.

Regulatory Transparency

While the transaction itself is minor in scale, it’s part of the ongoing stewardship of a sizable investment. These filings aren’t just compliance formalities—they reflect how large investors stay aligned across complex organizational structures. FMR’s position in Beam may have adjusted slightly, but their involvement remains deep and multilayered.

As with all such disclosures, this one falls under Section 16 of the Securities Exchange Act of 1934. It doesn't signal a strategy change, but it keeps the market informed and provides transparency into how major stakeholders are managing their capital. For anyone tracking institutional activity in the biotech space, these filings remain a key part of the picture.